Neil Miller, NRG Therapeutics CEO

GSK vets the­o­rize that a mi­to­chon­dr­i­al tar­get may un­lock Parkin­son's and ALS treat­ments in new start­up

Can tar­get­ing a mi­to­chon­dr­i­al path­way pre­vi­ous­ly thought to be un­drug­gable crack the code in dev­as­tat­ing neu­rode­gen­er­a­tive dis­eases, such as Parkin­son’s and ALS? For a new British start­up, that’s the £16 mil­lion ques­tion.

NRG Ther­a­peu­tics un­veiled its Se­ries A ear­ly Wednes­day morn­ing on the backs of two GSK vets and their re­search that, they claim, has pin­point­ed a way to pro­tect mi­to­chon­dria from the hall­mark neu­ronal dam­age seen in neu­rode­gen­er­a­tion. If every­thing goes ac­cord­ing to plan, the biotech could de­vel­op “dis­ease-mod­i­fy­ing” small mol­e­cule treat­ments for both Parkin­son’s and ALS, CEO Neil Miller told End­points News.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.